Compare AMETEK, Inc. (AME) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs HCA Health Inc — how do they compare? AMETEK, Inc. trades at $258.65 (market cap $58.76B), while HCA Health Inc trades at $413.85 (market cap $89.08B). The key difference: HCA Health Inc is the larger of the two by market cap, and HCA Health Inc pays the higher dividend (0.76%). Which is the better fit depends on your goals.
| AME | HCA | |
|---|---|---|
Market Cap | $58.76B | $89.08B |
Sector | Industrials | Health |
52-Week High | $256.30 | $545.13 |
52-Week Low | $179.28 | $361.32 |
Enterprise Value | $60.30B | $139.62B |
Dividend Yield | 0.53% | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME's stock trades at $257.9, up 1.99% today, reflecting strong momentum after recent earnings beats. The company reported record Q2 2026 results with EPS of $2.09, exceeding estimates, and raised full-year guidance. Valuation metrics like a P/E of 37.47 and P/S of 7.51 are elevated, but supported by robust profitability, including a 20.04% net income margin and 14.56% ROE. Technical indicators show a bullish trend, with the current price near resistance at $258.
The outlook remains positive, driven by consistent earnings growth and strong demand across business segments. Key risks include high valuation multiples and potential economic headwinds. With a consensus price target of $281.86 and no sell ratings from analysts, the stock offers upside potential, but investors should monitor execution against guidance and market volatility.
HCA Healthcare trades at $413.27, down 0.18% on the day, with strong technical momentum showing a bullish moving average signal. The company reported solid Q2 2026 earnings with EPS of $7.59 beating estimates of $7.56, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $75.60 billion, while maintaining healthy profit margins of 8.77%. Recent management appointments and ongoing legal investigations create mixed sentiment around the stock.
HCA presents a compelling value opportunity with attractive valuation multiples (P/E 13.8, EV/EBITDA 8.8) and strong analyst support (63% buy ratings, $449.93 price target). However, investors face risks from multiple ongoing legal investigations, high debt levels (debt-to-asset ratio 80.9% in 2025), and margin pressure from rising operational costs. The stock offers 8.9% upside to consensus target but requires monitoring of legal developments and expense management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
